Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
PHIBRO ANIMAL HEALTH CORP
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-69.0% vs price
Base Case (Median)
-47.4% vs price
Bull Case (75th pct.)
27.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $9.86 | -72.9% | High (40%) |
| PE Comparable | $54.23 | 49.2% | Medium (25%) |
| Graham Number | $22.80 | -37.3% | Medium (40%) |
| EV/EBITDA | $58.03 | 59.6% | Medium (20%) |
| EV/FCF | $4.87 | -86.6% | Medium (20%) |
| Earnings Power Value | $15.43 | -57.5% | Medium (50%) |
Based on 6 out of 8 methods, PAHC appears fairly valued at the current price of $36.35. The base case fair value of $19.12 implies 47.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
